Europe
New research program between BioNTech and the University of Pennsylvania
Equiteq, the knowledge economy M&A specialist, is pleased to announce that it has advised Essential Design (Essential), a Boston-based innovation strategy and product design business, on its sale to PA Consulting (PA), a global innovation and transformation consultancy.
VTT and Dyadic International, Inc. today announced that VTT scientists will present the excellent results in their collaboration over the past two years at two international conferences: AAPS PharmSci on November 7th in Washington DC and PEGS Europe on November 14th in Lisbon.
Microbiotica announces that it has been named Life Sciences Company of the Year at the Cambridge Independent Awards, which took place last night at the Hilton Cambridge City Centre Hotel.
Embark was first incubated by Novo Seeds and funded through the pre-seed grant programme of the Novo Nordisk Foundation in 2016
Cristal Therapeutics has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO).
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
The Garden State joins a long list of governments that have brought charges against opioid makers during an addiction crisis that claims the lives of 116 Americans per day.
Two weeks after acquiring two drugs from AstraZeneca in a $700 million deal, Germany-based Grünenthal flexed its M&A muscle again to acquire Averitas Pharma to extend its commercial footprint in the United States.
Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion.
PRESS RELEASES